<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176200</url>
  </required_header>
  <id_info>
    <org_study_id>215.1361</org_study_id>
    <nct_id>NCT02176200</nct_id>
  </id_info>
  <brief_title>Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide&#xD;
      50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and the same&#xD;
      dose of Berodual® delivered via an hydrofluoroalkane (HFA) - metered dose inhaler (2 x puffs&#xD;
      ) in COPD patients at different inspiratory flow rates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of dose in the whole lung</measure>
    <time_frame>immediately after dosing</time_frame>
    <description>disposition of aerosol via gamma scintigraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of dose in the central lung zone</measure>
    <time_frame>immediately after dosing</time_frame>
    <description>disposition of aerosol via gamma scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dose in the intermediate lung zone</measure>
    <time_frame>immediately after dosing</time_frame>
    <description>disposition of aerosol via gamma scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dose in the peripheral lung zone</measure>
    <time_frame>immediately after dosing</time_frame>
    <description>disposition of aerosol via gamma scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral zone/central zone deposition ratio (lung penetration index)</measure>
    <time_frame>immediately after dosing</time_frame>
    <description>disposition of aerosol via gamma scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentate of dose in oropharyngeal deposition</measure>
    <time_frame>immediately after dosing</time_frame>
    <description>disposition of aerosol via gamma scintigraphy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® Respimat®, low inspiratory flow rate</intervention_name>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® Respimat®, medium inspiratory flow rate</intervention_name>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® Respimat®, high inspiratory flow rate</intervention_name>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® HFA-MDI, low inspiratory flow rate</intervention_name>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® HFA-MDI, medium inspiratory flow rate</intervention_name>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berodual® HFA-MDI, high inspiratory flow rate</intervention_name>
    <arm_group_label>Berodual® HFA-MDI</arm_group_label>
    <arm_group_label>Berodual® Respimat®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must have a diagnosis of COPD and must meet the following spirometric&#xD;
             criteria:&#xD;
&#xD;
               -  Patients must have relatively stable, mild to severe airway obstruction with an&#xD;
                  forced expiratory volume in one second (FEV1) ≤70% of predicted normal and FEV1&#xD;
                  ≤70% of forced vital capacity (FVC). Predicted normal values calculated according&#xD;
                  to evolutionary conserved chromosome segments (ECCS)&#xD;
&#xD;
          -  Male or non-pregnant/non-lactating female patients aged ≥18 years&#xD;
&#xD;
          -  All patients must sign an informed consent form prior to participation in the study,&#xD;
             i.e. prior to pre-study washout of their usual pulmonary medications&#xD;
&#xD;
          -  Current or ex-smokers with a smoking history of &gt;10 pack years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significant diseases other than COPD will be excluded. A significant&#xD;
             disease is defined as a disease which in the opinion of the investigator may either&#xD;
             put the patient at risk because of participation in the study or a disease which may&#xD;
             influence the results of the study or the patient's ability to participate in the&#xD;
             study&#xD;
&#xD;
          -  Patients who have frequent exacerbations which could be expected to interfere with the&#xD;
             patient's ability to participate in the study should be excluded. The enrolment of&#xD;
             patients who have had an exacerbation within the six weeks prior to planned study&#xD;
             entry has to be postponed.&#xD;
&#xD;
          -  Patients with clinically relevant abnormal baseline haematology, blood chemistry or&#xD;
             urinalysis, if the abnormality defines a disease listed as an exclusion criterion will&#xD;
             be excluded&#xD;
&#xD;
          -  Patients with a recent history (i.e. six months or less) of myocardial infarction&#xD;
&#xD;
          -  Patients with any unstable or life-threatening cardiac arrhythmia or who have been&#xD;
             hospitalised for heart failure within the past year&#xD;
&#xD;
          -  Patients who regularly use daytime oxygen therapy for more than 1 hour per day and in&#xD;
             the investigator's opinion will be unable to abstain from the use of oxygen therapy&#xD;
&#xD;
          -  Patients with known active tuberculosis&#xD;
&#xD;
          -  Patients with a history of cancer within the last five years. Patients with treated&#xD;
             basal cell carcinoma are allowed&#xD;
&#xD;
          -  Patients with a history of life-threatening pulmonary obstruction, or a history of&#xD;
             cystic fibrosis or bronchiectasis&#xD;
&#xD;
          -  Patients who have undergone thoracotomy with pulmonary resection. Patients with a&#xD;
             history of thoracotomy for other reasons should be evaluated as per exclusion 1&#xD;
&#xD;
          -  Patients with any upper respiratory infection in the past 14 days prior to the&#xD;
             screening visit or during the baseline period or lower respiratory tract infection&#xD;
             within the last 3 months&#xD;
&#xD;
          -  Patients who are currently in a pulmonary rehabilitation programme or who have&#xD;
             completed a pulmonary rehabilitation programme in the six weeks prior to the screening&#xD;
             visit&#xD;
&#xD;
          -  Patients with known hypersensitivity to β2-agonists, anticholinergic drugs or any&#xD;
             excipients of the active or placebo Berodual®&#xD;
&#xD;
          -  Patients with known narrow-angle glaucoma&#xD;
&#xD;
          -  Patients who are being treated with cromolyn sodium or nedocromil sodium&#xD;
&#xD;
          -  Patients who are being treated with antihistamines (H1 receptor antagonists)&#xD;
&#xD;
          -  Patients using oral corticosteroid medication at unstable doses (i.e. less than six&#xD;
             weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of&#xD;
             prednisolone per day or 20 mg every other day&#xD;
&#xD;
          -  Patients who are being treated with monamine oxidase inhibitors or tricyclic&#xD;
             antidepressants&#xD;
&#xD;
          -  Pregnant or nursing women or women of childbearing potential not using a medically&#xD;
             approved means of contraception (i.e. oral or injectable eg Depo-Provera or Noristerat&#xD;
             contraceptives, intrauterine devices, diaphragm plus spermicide or subdermal implants&#xD;
             eg: Norplant®)&#xD;
&#xD;
          -  Patients with, in the opinion of the investigator, a history of and/or active&#xD;
             significant alcohol or drug abuse&#xD;
&#xD;
          -  Patients who have taken an investigational drug within four months or six half lives&#xD;
             (whichever is the greater) prior to screening visit and/or the administration of&#xD;
             radiolabelled dosage forms within the three months prior to the screening visit&#xD;
&#xD;
          -  Radiation exposure from clinical studies, including that from the present study and&#xD;
             diagnostic X-rays but excluding background radiation, exceeding 5 millisievert (mSv)&#xD;
             in the last 12 months or 10 mSv in the last five years. No patient whose occupational&#xD;
             exposure is monitored will participate in the study&#xD;
&#xD;
        Precautions: As with other anticholinergic drugs, Berodual® should be used with caution in&#xD;
        patients with prostatic hyperplasia or bladder neck obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/215/215.1361_U05-1746.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenoterol</mesh_term>
    <mesh_term>Fenoterol, ipratropium drug combination</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

